NewsBenzingaAcumen Pharmaceuticals présentera de nouvelles données de phase 2 ALTITUDE-AD sur le sabirnetug dans la maladie d’Alzheimer à un stade précoce lors du CTAD 2026 Acumen Pharmaceuticals présentera de nouvelles données de phase 2 ALTITUDE-AD sur le sabirnetug dans la maladie d’Alzheimer à un stade précoce lors du CTAD 2026 Benzinga 2026.10.22 11:36 (GMT+0) Open on Benzinga Other news Wolfe Research Initiates Coverage On Abercrombie & Fitch with Outperform Rating, Announces Price Target of $181 Evercore ISI Group Maintains Outperform on Meta Platforms, Raises Price Target to $870 Dow Warns High Interest Rates and Weak Consumer Confidence Are Hurting Housing Demand Evercore ISI Group Maintains Outperform on Knight-Swift, Raises Price Target to $79 Wolfe Research Initiates Coverage On Lululemon Athletica with Underperform Rating, Announces Price Target of $75 Stock of the Day: Where is the Bottom for AT&T?
Wolfe Research Initiates Coverage On Abercrombie & Fitch with Outperform Rating, Announces Price Target of $181
Wolfe Research Initiates Coverage On Lululemon Athletica with Underperform Rating, Announces Price Target of $75
